Baird rates Exactech as ‘outperform’: 4 insights

Baird, a brokerage firm, upgraded its analysis of Exactech to “outperform,” according to The Market Digest.

Advertisement

Here are four insights:

 

1. Baird previously rated the company as “neutral.”

 

2. On April 15, Exactech’s stock ended at $21.96.

 

3. The company’s 52-week high is $25.74 and the 52-week low is $16.11.

 

4. Exactech has a market capitalization of $308 million.

 

More articles on devices:
Orthofix shares reach new 1-year high: 3 points
1k Hunter Medical’s ElbowLOC Arm Positioning System procedures complete: 3 notes
Dr. Robert Rovner uses Coflex as an alternative treatment for spinal stenosis — 5 highlights

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

  • From new technology acquisitions to regulatory clearances to leadership changes, here are 20 developments and updates from the biggest players…

  • SurGenTec’s ION-C earned FDA 510(k) clearance for ION-C navigation instruments with the ION-C posterior cervical facet fixation implant, according to…

  • VB Spine has made big pushes into the spine medtech space so far in 2026, including global expansions. Six headlines…

Advertisement

Comments are closed.